Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.0K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Novel C-Terminal Cystine Knot (Exon 52) VWF p.Cys2771Phe Variant Produces a Type 2A von Willebrand Factor Multimer Pattern with an Apparent Dimerization Defect.

Seminars in thrombosis and hemostasis·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026
Same author

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

bioRxiv : the preprint server for biology·2026
Same author

Reusing Blood Samples from a Hospital-based Cohort to Apixaban Plasma Concentrations.

medRxiv : the preprint server for health sciences·2026
Same author

Corrigendum: Investigation of the Influence of Lipoprotein(a) and Oxidized Lipoprotein(a) on Plasminogen Activation and Fibrinolysis.

Journal of lipid and atherosclerosis·2026
Same author

Abnormal von Willebrand factor multimer pattern without <i>VWF</i> variants in autosomal-recessive cutis laxa type IIA.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Exploring the Role of Hypusine Signaling in Vascular Smooth Muscle Cells for Mitigating Restenosis in Coronary Artery Disease.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Circulating Extracellular Mitochondria Perpetuate Endothelial Damage via Cardiolipin-Mediated Mitophagic Overload.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Myeloid Cell-Specific Deletion of LGR4 Suppresses Atherosclerotic Lesion Formation.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Building Resilience in Academic Science and Medicine.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Endothelial Continuum and Capillary Specialization in Pulmonary Vascular Development.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Systematic Review and Meta-Analysis Examining the Effect of Upregulation and Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 in Mouse Models of Abdominal Aortic Aneurysm.

Arteriosclerosis, thrombosis, and vascular biology·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Factor XI as a Therapeutic Target.

David Gailani1, Andras Gruber2

  • 1From the Department of Pathology, Microbiology and Immunology and Department of Medicine, Vanderbilt University, Nashville, TN (D.G.); and Aronora, Inc, Portland, OR (A.G.). dave.gailani@vanderbilt.edu.

Arteriosclerosis, Thrombosis, and Vascular Biology
|May 14, 2016
PubMed
Summary
This summary is machine-generated.

Targeting factor XIa, an enzyme involved in blood clotting, may offer antithrombotic benefits with minimal impact on hemostasis. This approach shows promise for preventing venous thrombosis, as indicated by recent clinical trial results.

Keywords:
factor XIfactor XIIhemorrhagethrombinthrombosis

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Related Experiment Videos

Last Updated: Mar 21, 2026

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Area of Science:

  • Biochemistry
  • Physiology
  • Pathology

Background:

  • Factor XIa is a serine protease crucial for thrombin generation.
  • Emerging evidence links Factor XIa to both coagulation and the kallikrein-kinin system.
  • Factor XI deficiency results in mild bleeding, suggesting a therapeutic window.

Purpose of the Study:

  • To review recent findings on Factor XI and XIa.
  • To explore the role of Factor XIa in thromboembolic disease.
  • To discuss the potential of targeting Factor XI/XIa for antithrombotic therapy.

Main Methods:

  • Review of animal models and epidemiological data.
  • Analysis of clinical observations regarding Factor XI deficiency.
  • Evaluation of recent clinical trial data on Factor XI reduction.

Main Results:

  • Factor XIa acts as an interface between coagulation and inflammation.
  • Factor XIa plays a role in thromboembolic disorders.
  • Antisense-induced Factor XI reduction shows promise in preventing venous thrombosis.

Conclusions:

  • Targeting Factor XI or XIa may provide antithrombotic effects with preserved hemostasis.
  • Factor XIa represents a potential therapeutic target for thromboembolic diseases.
  • Further research into Factor XIa's role is warranted for clinical applications.